Sep 05, Philips introduces computational pathology software for automated prostate and cancer ovarian detection tumor detection at ECP Artificial Intelligence AI -powered TissueMark  software enables molecular research labs to reduce variability in tumor estimation and related costs Amsterdam, The Netherlands and Bilbao, Spain — Royal Philips NYSE: PHG, AEX: PHIAa global leader in health technology, today announced the latest release of TissueMarkwhich now supports region of interest detection for the majority of molecular testing and helps research labs improve the accuracy of tumor estimation.
The new version, which will be showcased at the 30th European Congress of Pathology ECPfrom September at Euskalduna Conference Centre, leverages deep learning AI to aid in prostate and ovarian tumor tissue identification. Prostate cancer is the second deadliest cancer for men and ovarian cancer is the fifth deadliest for women. Given the severity of these two cancers, it is increasingly important that pathologists are equipped with the technology they need to further their research cancer ovarian detection these important areas.
Innovative computational solutions can help pathologists improve efficiency in the research setting, which will ultimately help support precision medicine and enhance the speed and accuracy of cancer ovarian detection. In addition to providing tumor sufficiency guidance for lung histology, lung cytology, colon and breast tissue samples in 60 seconds, the updated TissueMark software now provides this guidance to whole slide images WSI of adenocarcinoma prostate tissue and high-grade cancer ovarian detection carcinoma ovarian tissue.
Prevention and Early Detection of Ovarian Cancer
With this update, TissueMark presents a comprehensive portfolio of AI-driven applications to address most critical primary tumors encountered for molecular research testing. Philips is at the forefront of using advanced analytics and artificial intelligence in key healthcare domains and launched its AI platform for healthcare earlier this year. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions.
Profilul de risc clinic asociat cancerului ovarian This study was performed to evaluate the clinical risk profile of patients with ovarian tumors who were surgically treated, measuring the survival cancer ovarian detection at 5 years. Furthermore, the surgical treatment by TNM stages was achieved, measuring the survival rate after five years of follow-up. Most of the patients with malignant disease were multiparous Moreover, from menopausal patients, the higher prevalence was seen at the group between 45 and 55 years old, not being dependent on the earlier appearance. Abstract Background The outcome of breast cancer treatment largely depends on the timing of detection. The health promotion interventions have an immense contribution to early detection and improved survival.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips cancer ovarian detection sales of EUR News about Philips can be found at www.